This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, H. Articles by Weber, W. Search for Related Content PubMed PubMed Citation Articles by Su, H. Articles by Weber, W. Related Collections Commentary

Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors

Authors' Affiliations: ¹ Department of Molecular Medicine and Pharmacology, ² Jonsson Comprehensive Cancer Center, ³ Department of Biological Chemistry, and ⁴ Ahmanson Biological Imaging Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Requests for reprints: Wolfgang Weber, Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, CHS AR-274, 650 Charles Young Drive, South Los Angeles, CA 90095. Phone: 310-206-2179; Fax: 310-206-4899; E-mail: wweber{at}mednet.ucla.edu.

Purpose: The mechanisms underlying the sensitivity of non–small cell lung cancer to epidermal growth factor receptor (EGFR) kinase inhibitors are complex, and there are no established markers to accurately predict treatment outcome in individual patients.

Experimental Design: We investigated whether tumors responding to EGFR inhibitors can be identified by measuring treatment-induced changes in glucose utilization by positron emission tomography with the glucose analogue fluorodeoxyglucose (FDG-PET). We studied a panel of cell lines with a spectrum of sensitivity to EGFR kinase inhibitors. After incubation with the EGFR kinase inhibitor gefitinib for various time points, FDG uptake, glucose transport rates, and hexokinase activity were determined. FDG uptake in vivo was assessed by microPET imaging of tumor xenografts in mice.

Results: In gefitinib-sensitive cell lines, there was a dramatic decrease in FDG uptake as early as 2 hours after treatment. Immunoblots showed the translocation of glucose transporters (GLUT3) from the plasma membrane to the cytosol; glucose transport rates were reduced 2.6-fold at this time. There was also a modest reduction of hexokinase activity. These metabolic alterations preceded changes in cell cycle distribution, thymidine uptake, and apoptosis. MicroPET studies showed an up to 55% decrease of tumor FDG uptake in sensitive xenografts within 48 hours. In contrast, gefitinib-resistant cells exhibited no measurable changes in FDG uptake, either in cell culture or in vivo.

Conclusion: Glucose metabolic activity closely reflects response to gefitinib therapy. FDG-PET may be a valuable clinical predictor, early in the course of treatment, for therapeutic responses to EGFR kinase inhibitors.

Commentary

Monitoring Targeted Therapy: Is Fluorodeoxylucose Uptake a Marker of Early Response?

Hannah M. Linden, Kenneth A. Krohn, Robert B. Livingston, and David A. Mankoff
Clin. Cancer Res. 2006 12: 5608-5610. [Full Text] [PDF]

This article has been cited by other articles:

				K. B. Contractor and E. O. Aboagye Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET J. Nucl. Med., May 1, 2009; 50(Suppl_1): 97S - 105S. [Abstract] [Full Text] [PDF]

				R. J. Hicks Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 31S - 42S. [Abstract] [Full Text] [PDF]

				H. Schoder, M. Fury, N. Lee, and D. Kraus PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 74S - 88S. [Abstract] [Full Text] [PDF]

				R. A. Dumont, I. Hildebrandt, H. Su, R. Haubner, G. Reischl, J. G. Czernin, P. S. Mischel, and W. A. Weber Noninvasive Imaging of {alpha}V{beta}3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib Cancer Res., April 1, 2009; 69(7): 3173 - 3179. [Abstract] [Full Text] [PDF]

				B. Zhao, L. H. Schwartz, and S. M. Larson Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers J. Nucl. Med., February 1, 2009; 50(2): 239 - 249. [Abstract] [Full Text] [PDF]

				G. Z. Ferl, R. A. Dumont, I. J. Hildebrandt, A. Armijo, R. Haubner, G. Reischl, H. Su, W. A. Weber, and S.-C. Huang Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing Mice J. Nucl. Med., February 1, 2009; 50(2): 250 - 258. [Abstract] [Full Text] [PDF]

				J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]

				M.-C. Crouthamel, J. A. Kahana, S. Korenchuk, S.-Y. Zhang, G. Sundaresan, D. J. Eberwein, K. K. Brown, and R. Kumar Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia Clin. Cancer Res., January 1, 2009; 15(1): 217 - 225. [Abstract] [Full Text] [PDF]

				E. T. Lam, C. L. O'Bryant, M. Basche, D. L. Gustafson, N. Serkova, A. Baron, S. N. Holden, J. Dancey, S. G. Eckhardt, and L. Gore A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors Mol. Cancer Ther., December 1, 2008; 7(12): 3685 - 3694. [Abstract] [Full Text] [PDF]

				D. A. Mankoff and J. F. Eary Proliferation Imaging to Measure Early Cancer Response to Targeted Therapy Clin. Cancer Res., November 15, 2008; 14(22): 7159 - 7160. [Abstract] [Full Text] [PDF]

				H. C. Manning, N. B. Merchant, A. C. Foutch, J. M. Virostko, S. K. Wyatt, C. Shah, E. T. McKinley, J. Xie, N. J. Mutic, M. K. Washington, et al. Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7413 - 7422. [Abstract] [Full Text] [PDF]

				H.-J. Sohn, Y.-J. Yang, J.-S. Ryu, S. J. Oh, K. C. Im, D. H. Moon, D. H. Lee, C. Suh, J.-S. Lee, and S.-W. Kim [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung Clin. Cancer Res., November 15, 2008; 14(22): 7423 - 7429. [Abstract] [Full Text] [PDF]

				L. H. Wei, H. Su, I. J. Hildebrandt, M. E. Phelps, J. Czernin, and W. A. Weber Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma Clin. Cancer Res., June 1, 2008; 14(11): 3416 - 3426. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				C. Suzuki, H. Jacobsson, T. Hatschek, M. R. Torkzad, K. Boden, Y. Eriksson-Alm, E. Berg, H. Fujii, A. Kubo, and L. Blomqvist Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations RadioGraphics, March 1, 2008; 28(2): 329 - 344. [Abstract] [Full Text] [PDF]

				S.-L. Song, J.-J. Liu, G. Huang, Z.-H. Wang, Y.-Y. Song, X.-G. Sun, and T. Chen Changes in 18F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model J. Nucl. Med., February 1, 2008; 49(2): 303 - 309. [Abstract] [Full Text] [PDF]

				J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET J. Nucl. Med., January 1, 2008; 49(1): 129 - 134. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and N. Thatcher Introduction Oncologist, January 1, 2008; 13(suppl_1): 1 - 4. [Abstract] [Full Text] [PDF]

				G. J. Riely, M. G. Kris, B. Zhao, T. Akhurst, D. T. Milton, E. Moore, L. Tyson, W. Pao, N. A. Rizvi, L. H. Schwartz, et al. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus Clin. Cancer Res., September 1, 2007; 13(17): 5150 - 5155. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				W. A. Weber and R. Figlin Monitoring Cancer Treatment with PET/CT: Does It Make a Difference? J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S. [Abstract] [Full Text] [PDF]

				H. M. Linden, K. A. Krohn, R. B. Livingston, and D. A. Mankoff Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response? Clin. Cancer Res., October 1, 2006; 12(19): 5608 - 5610. [Full Text] [PDF]